Slide 1: Craneware plc H1 FY26 Interim Results
Craneware plc Keith Neilson, CEO Craig Preston, CFO H1 FY26 Interim Results March 2026 © 2026 Craneware, Inc. All rights reserved. This document is confidential, is protected by trade secret laws, and may not be copied or disseminated in any form, including electronically. 1
Slide 2: We partner with healthcare providers across the US
We partner with healthcare Financially strong providers across the US to improve and sustain their +$184m ARR, NRR of 103% operational and financial Average relationship of top 10 performance. customers is 20 years c.90% of revenue is recurring Our innovative software 30%+ EBITDA margins solutions e
Slide 3: Strong performance across the Group
Strong performance across the Group Strategic progress driving momentum RESULTS STRENGTH OPPORTUNITY Strong financial Good sales performance, Accelerated innovation is performance and good including increased growing our TAM progress across key competitive takeout rate metrics © 2026 Craneware, Inc.
Slide 4: Another positive sales performance
Another positive sales performance Continued strong expansion sales and increased competitive wins H1 FY26 - Annual Value of 'new' Sales Increase in new hospitals secured (12% v 2% H1 FY25) • Each with considerable expansion potential. Revenue New Hospitals, recognition commences in H2 12% Increased
Slide 5: 340B's vital role in US healthcare
340B’s vital role in US healthcare Drug spend continues to grow - the Pharma margins remain high - at 340B Program plays vital role in making median price of new drugs has increased +20%, on average drugs more affordable to eligible 50% per year in the last few years populations, funded by Pharmaceu
Slide 6: Our response to the 340B Rebate Pilot Program
Our response to the 340B Enabling our customers to Rebate Pilot Program navigate change, with confidence Integrated, enterprise grade solution ready for launch within 120 days – AI provided significant AI tools productivity gains Providing customers with confidence in their Only vendor 340B ability
Slide 7: H1 FY26 Financial Results
H1 FY26 Financial Results © 2026 Craneware, Inc. All rights reserved. This document is confidential, is protected by trade secret laws, and may not be copied or disseminated in any form, including electronically. 7
Slide 8: A healthy performance in H1 FY26
A healthy performance in H1 FY26 $105.7m +6% H125: $100.0m $33.4m +10% H125: $30.3m 58.7 +16% H125: 50.6 Revenue Adj. EBITDA Adj. EPS (cents) $184.2m 85% $23.4m (26%) H125: $177.3m H125: 110% H125: $31.6m ARR 12 mth Operating Cash Conversion Total Bank Debt © 2026 Craneware, Inc. All rights reserved
Slide 9: H1 2026 Review: Results
Revenue (millions) $120 $100 $80 $60 105.7 91.2 100.0 $40 84.7 80.2 $20 H1 2026 Review: Results $0 H122 H123 H124 H125 H126 Adj. EBITDA (millions) $40 Revenue and earnings growth $30 $20 33.4 30.3 ─ Revenue increased to $105.7m +6% $10 23.7 25.5 27.5 (H125: $100m) $0 H122 H123 H124 H125 H126 ─ Adj E
Slide 10: H1 2026 Review: Results (cash)
H1 2026 Review: Results Cash ($m) • Strong cash management supports continued investment 100 Sentry Acquisition H1 2026 H1 2025 $000 $000 Cash in transit 80 Cash at period end $71.2m Cash generated from operations 16,269 65,775 Tax paid (8,690) (8,538) 60 after adjusting for cash in Net cash from op
Slide 11: Annuity SaaS Model
Annuity SaaS Model Driving contracted recurring revenue $m 200 200 SaaS Software Revenue Contracted Recurring 180 180 Typical multi-year underlying contracts 184.2 177.3 ─ High visibility of future revenues 160 160 171.4 Revenue 140 140 Other recurring revenue A proportion of Platform 120 120 ─ Mont
Slide 12: Income Statement & EPS
Income Statement & EPS H1 2026 H1 2025 FY 2025 Income Statement #039;000 #039;000 #039;000 Headline Results Revenue 105,722 100,045 205,657 Revenue Adj. EBITDA Adj. Basic EPS* Cost of sales (16,053) (13,159) (26,384) Gross profit Other income Operating expenses 89,669 9 (75,443) 86,886 - (74,871) 179,273 57
Slide 13: Strong Balance Sheet
H1 2026 H1 2025 FY 2025 Strong Balance Sheet ASSETS Non-Current Assets $000 $000 $000 Property, plant and equipment 5,501 7,514 6,252 Intangible assets - goodwill 235,236 235,236 235,236 Intangible assets - acquired intangibles 114,024 134,946 124,485 Intangible assets – other 64,001 59,076 61,243 T
Slide 14: Capital Allocation
Capital Allocation Balancing the needs of our stakeholders Progressive dividend policy plus Rapidly paid down debt, while in high- Maintain R&D spend of approx. 25% of buybacks has seen $66.1m (c£51.6m*) interest rate environment, delivering revenues, as we see considerable returned to shareholders
Slide 15: Growth strategy & opportunity
Growth strategy & opportunity © 2026 Craneware, Inc. All rights reserved. This document is confidential, is protected by trade secret laws, and may not be copied or disseminated in any form, including electronically. 15
Slide 16: The right foundations for today and tomorrow
The right foundations for today and tomorrow At the frontier of embedded AI Scale Reputation Industry Delivering long-term value creation, Embedded ROI 40% of US Best in KLAS Expertise across customer value drivers with a clear path to AI monetisation hospitals for 15th time +26 years functions for
Slide 17: Innovation to support our customers and expand our TAM
Innovation to support our customers and expand our TAM Major increase in embedded Trisus capabilities in H2 FY26 Trisus Assist Trisus Assist for Reimbursement Trisus Labor & Productivity Intelligence AI-powered assistant streamlines AI-enhanced demand forecasting and AI-powered contract structuring
Slide 18: Three catalysts for growth
Three catalysts for growth Existing 8x revenue opportunity, from existing solutions customer Innovation and ROI supporting continued expansion with existing customers expansion Two major product releases in H2 FY26, supporting FY27 revenue growth Win new 60% of the market still available customers M
Slide 19: H2 FY26 Focus areas & strategic objectives
H2 FY26 Focus areas & strategic objectives T INNOVATION PLATFORM Launching two major Capitalising on HIMSS Further leveraging Trisus AI-powered solutions activity, joint GTM & co- platform to provide marketing unique customer insights to delight & grow © 2026 Craneware, Inc. All rights reserved. Thi
Slide 20: Unique strengths underpin future revenue growth acceleration
Unique strengths underpin future revenue growth acceleration Supporting sustainable, long-term value generation Opportunity $184m Disciplined remains ARR dynamic unlocks market capital allocation new considerable opportunities and 103% NRR to drive continue to provide strong shareholder accelerate b
Slide 21: Appendix
uic CIOlleWwa#ie QGioup Transforming the Business of Healthcare™ Appendix
Slide 22: General information
Major shareholders % of Issued Shareholder General information Share Capital Keith Neilson (CEO & co-founder) 8.97% • Share Price 1515p (at 27/02/2026) Octopus Investments 7.05% • Market AIM Liontrust Asset Management 6.53% • Ticker CRW • Market Cap. £525m Gordon Craig (co-founder) 5.83% • Ord. shar